Inhalation Research Services chosen for new research project worth 1.45 million SEK by US pharma company Kumar Jeetendra | July 18, 2022 (Stockholm 18 July 2022) A US company with an extensive pipeline in medical dermatology has chosen Inhalation Research Services (IRS), ISAB’s contract research organization, for a research project worth 1.45 million SEK (1.36 K Euro) into a new repurposed drug that is being reformulated for administration via the lungs. ISAB’s world-class expertise in inhalation, and …
Cipla receives USFDA approval for generic version of Revlimid® (lenalidomide capsules) Kumar Jeetendra | September 7, 2022 Mumbai, India/ New Jersey, United States, September 7, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) (“Cipla”) announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsule 5 mg, 10 mg, 15 mg and 25 mg from the United States Food and Drug Administration (US FDA). Cipla’s Lenalidomide …
WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers Kumar Jeetendra | September 10, 2022 SHANGHAI, Sept. 9, 2022– WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its Wuxi city campus. Created in response to the increasing demand for complex injection dosage forms, this new facility adds to the company’s fast-growing parenteral formulation capabilities and is …
Baxter strengthens its R&D capabilities with the inauguration of the global Pharmaceuticals R&D Centre in Ahmedabad, India Kumar Jeetendra | October 17, 2022 Baxter Pharmaceuticals India Pvt. Ltd., today announced the inauguration of a global Pharmaceuticals R&D Centre in Ahmedabad, India. The Centre will help further the company’s mission of saving and sustaining lives by accelerating innovation in the generic and differentiated injectable pharmaceuticals space. The R&D Centre was inaugurated by Mr. Alok Sonig, President, Pharmaceuticals, Baxter International Inc. …
Aragen to operationalize cutting-edge formulation manufacturing facility Kumar Jeetendra | October 21, 2022 Aragen, a leading Contract Research Development and Manufacturing Organization (CRDMO), today announced that it will operationalize its state-of-the-art formulation manufacturing facility in the Mallapur campus, Hyderabad, India by January 2023. The 12,000 square feet new facility will strengthen the company’s ability to deliver clinical supplies to customers through its integrated drug substance and drug product …
Alembic Pharmaceuticals announces its first injectable product approval from its General Sterile Facility – Final Approval for Glycopyrrolate Injection USP Kumar Jeetendra | November 1, 2022 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Glycopyrrolate Injection USP, 0.2 mg/1 mL and 0.4 mg/2 mL (0.2 mg/mL) Single-dose Vials and 1 mg/5 mL (0.2 mg/mL) and 4 mg/20 mL (0.2 mg/mL) Multiple-dose Vials. …
Cipla EU to invest EUR 15 million in ETHRIS, initiating a strategic collaboration Kumar Jeetendra | December 29, 2022 Mumbai, India and Munich, Germany: December 29, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced that its wholly owned UK subsidiary, Cipla (EU) Limited (“Cipla EU”) has signed definitive agreements for equity investment of EUR 15 million in Ethris GmbH (“Ethris”), a global leader in delivering mRNAs directly to …
CIPLA launches CIPPOINT, a point-of-care gadget for non-communicable, infectious, and other disorders. Kumar Jeetendra | January 20, 2023 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced the launch of Cippoint, a point-of-care testing device. This state-of-the-art device offers a wide range of testing parameters including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers. The device is CE IVD approved – …
Longevity science company Human Edge signs MoU with IIT Bombay Kumar Jeetendra | May 9, 2023 In its endeavour to fortify its technological capabilities, Human Edge, an investor-funded longevity science company, has announced its partnership with the Indian Institute of Technology, Bombay. Human Edge has been welcomed as the latest member of the Industry Research Partnership Program (IRPP) of Wadhwani Research Centre for Bioengineering (WRCB), a world-class translational research centre at …
Cipla launches CIPLAMED 2.0 – knowledge-sharing platform for Healthcare Practitioners (HCPS) Kumar Jeetendra | August 16, 2023 Mumbai, India; 16th August 2023: Cipla announced the launch of CiplaMed 2.0, an enhanced version of the industry-leading knowledge platform for the medical fraternity. In line with its digital transformation agenda, Cipla is pioneering an integrated omnichannel experience for healthcare professionals that seamlessly combines in-clinic interactions with digital engagement and access to medical information. This …
Actor Pharma (PTY) ltd will be acquired by Cipla Medpro South Africa (PTY) ltd (“CIPLA South Africa”) Kumar Jeetendra | September 4, 2023 Cipla South Africa, a 100% owned subsidiary of Cipla Limited(BSE: 500087; NSE: CIPLA EQ; hereafter referred to as “Cipla”) signed a binding term sheet with Actor Holdings (Pty) Limited to acquire 100% of the issued ordinary shares of Actor Pharma (Pty) Limited (“Actor”). This development underpins Cipla’s commitment and investment in its over the counter …
How constructive criticism drives Innovation in Pharma leadership Kumar Jeetendra | October 28, 2023 Constructive criticism plays a crucial role in driving innovation in pharmaceutical leadership. Here’s how it contributes to fostering a culture of innovation in the pharmaceutical industry: Finding shortcomings and Gaps: Leaders can find areas for development in their plans and processes by using constructive criticism to point out shortcomings and gaps. Leaders who are aware …
